Tenax TherapeuticsTENX +5.17%22 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 936 Biotechnology companies, Tenax Therapeutics ranks worse than 106837.5% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tenax Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-16.57 Mil. Tenax Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Tenax Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tenax Therapeutics EBITDA Margin % Related Terms
Tenax Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tenax Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TENX vs RCKT, AVIR, VNDA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Tenax Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenax Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tenax Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics (TENX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tenax Therapeutics and its competitors. According to the industry distribution chart, Tenax Therapeutics ranks #999999 out of 936 companies in the Biotechnology industry.
Is Tenax Therapeutics' EBITDA Margin % too high?
Tenax Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Tenax Therapeutics ranks #999999 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' EBITDA Margin % compare to RCKT and AVIR?
According to the Biotechnology industry distribution chart, Tenax Therapeutics ranks #999999 out of 936 companies for EBITDA Margin %. This places Tenax Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tenax Therapeutics and its competitors. Tenax Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Tenax Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score
Get the complete analysis for TENX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TENX has been successfully added to your 
